Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT)
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Sponsor: Clinical Research Technology S.r.l.
This PHASE2 trial investigates Metastatic Melanoma and is currently completed. Clinical Research Technology S.r.l. leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Research Technology S.r.l.
- Fondazione Melanoma Onlus
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece , Barcelona, Spain , Bari, Italy , Bergamo, Italy , Genova, Italy , Graz, Austria , London, United Kingdom , Manchester, United Kingdom , Meldola, Italy , Milan, Italy and 15 more locations